arrow
H

Hirohiko Shibayama

osaka national hospital
H指数:33
被引数:4,862

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

从关西骨髓瘤论坛对极高龄多发性骨髓瘤治疗的见解

2025-12-310
PRE
Preliminary analysis of a multicenter study of Pola-R-CHP in untreated Japanese patients with DLBCL (POLASTAR)

POLASTAR研究:Pola-R-CHP在未经治疗的日本DLBCL患者中的多中心初步分析

2025-12-010
OA
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients
2024-08-210
PRE
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

daratumumab后elotuzumab治疗多发性骨髓瘤的疗效恶化: 一项多中心回顾性研究

2024-03-161
PRE
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

日本复发/难治性多发性骨髓瘤患者伊扎佐米联合来那度胺-地塞米松的前瞻性、多中心、观察性研究

2023-09-112
OAAI
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
2023-03-295
OAAI
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study

Anti-CD38抗体isatuximab单药治疗日本复发/难治性多发性骨髓瘤患者: 1/2期岛屿研究的更新

2022-12-150
OAAI
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
2022-12-132
OAAI
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

复发或难治性外周T细胞淋巴瘤患者口服HDAC抑制剂tucidinostat: IIb期结果

2022-10-0635
OAAI
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

卡非佐米-来那度胺-地塞米松和卡非佐米-地塞米松在复发/难治性多发性骨髓瘤中的真实世界有效性和安全性分析: 多中心回顾性分析

2022-06-248
OAAI
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
2021-03-281
PRE
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study
2021-02-1615
OAAI
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
2020-03-0172
PREAI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Brentuximab vedotin联合化疗治疗CD30-positive外周T细胞淋巴瘤 (ECHELON-2): 一项全球性、双盲、随机、3期临床试验

LANCET
IF88.5
2019-01-01535
OAAI